Jim Rodberg is recorded as CFO at Sight Sciences, Inc. (SGHT) since January 9, 2023. Sight Sciences, Inc. reported in an 8-K filed April 3, 2023 that Jim Rodberg resigned as interim Chief Financial Officer, interim Treasurer, Principal Financial Officer or Principal Accounting Officer, effective April 3, 2023. Sight Sciences, Inc. reported in an 8-K filed January 9, 2023 that Jim Rodberg was appointed Interim Chief Financial Officer and Treasurer, effective January 9, 2023. Jim Rodberg has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Sight Sciences, Inc. on November 4, 2026. Sight Sciences, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Sight Sciences, Inc. includes Paul Badawi (CEO and Board Member), James Rodberg (CFO), Alison Bauerlein (COO) and 7 others.
“In connection with Ms. Bauerlein's appointment as Chief Financial Officer and Treasurer, Jim Rodberg will no longer serve as interim Chief Financial Officer, interim Treasurer, Principal Financial Officer or Principal Accounting Officer, effective immediately.”
Sight Sciences, Inc. Form 8-K, filed April 3, 2023
· Read the filing
“Effective January 9, 2023, Jim Rodberg, the Company’s Vice President of Finance and Corporate Controller, was appointed by the Board of Directors of the Company (the “Board”) to serve as interim Chief Financial Officer and Treasurer until the appointment of Mr. Selnick’s successor.”
Sight Sciences, Inc. Form 8-K, filed January 9, 2023
· Read the filing
Jim Rodberg on recent calls
“Third quarter revenue was a record $24.9 million, an increase of 25% year over year, and our third consecutive quarter of double-digit growth.”
“And, as Paul said, excited to be back in growth mode. And I think for us it's really the underlying metrics of both businesses. So 13% growth in Q1, 20% growth in Q2, as you said.”
“Before discussing the first quarter results, I want to underscore that we are executing against our strategic goals from a position of strength with the operating discipline and cost structure we need to support growth and we believe this positions us to achieve cash flow break even without the need to raise…”
“Total revenue for the fourth quarter was $20.5 million, representing 40% growth year-over-year and 10% growth sequentially. Surgical Glaucoma revenues for the fourth quarter were $18.8 million, up 35% year-over-year and up 10% sequentially.”
